Market Size of Netherlands Pharmaceutical Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Market Size (2024) | USD 9.92 Billion |
Market Size (2029) | USD 14.24 Billion |
CAGR (2024 - 2029) | 7.50 % |
Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Netherlands Pharmaceutical Market Analysis
The Netherlands Pharmaceutical Market size is estimated at USD 9.92 billion in 2024, and is expected to reach USD 14.24 billion by 2029, growing at a CAGR of 7.5% during the forecast period (2024-2029).
The COVID-19 pandemic had a significant impact on the market in its early phase due to various lockdown regulations that were imposed. For instance, according to an article published by PubMed Central in January 2021, a cross-sectional study was performed, which showed that there was a considerable impact of the COVID-19 pandemic on both logistic procedures and services in the pharmacies of the Netherlands. The reduction in such services meant fewer pharmaceutical sales. Hence, the COVID-19 pandemic had a significant impact on the market initially. However, post pandemic the market studied is expected to have stable growth during the forecast period of the study.
The presence of world-class research institutes, a highly educated workforce, an excellent healthcare system, and an innovation-friendly government, combined with a central location, makes the country an ideal base for biopharmaceutical operations. Healthcare and medical spending have increased over the past few years, reflecting strong potential for new medicine development, infrastructure building, and new entry/expansion opportunities. At the same time, the government is taking various initiatives to lower the prices of pharmaceutical products, which is expected to have adverse effects on the profitability of pharmaceutical companies. The Netherlands is expected soon negotiate lowering drug prices with pharmaceutical companies.
As per the data published by the Dutch Cancer Society (KWF), in 2021, cancer was the leading cause of death in the Netherlands. According to the same data, in 2021, an estimated 44,996 persons died of cancer, out of which 24,266 were men, and 20,730 were women. Furthermore, according to the data published by the World Bank, in 2022, the prevalence of diabetes as a percentage of the population aged between 20 and 79 was 4.5% in the Netherlands in 2021. Hence with the increasing burden of various diseases, it is expected that there will be steady growth in the market.
Therefore, owing to the aforementioned factors, the market is anticipated to witness growth over the forecast period. However, the high failure rate and developing cost of new products are likely to impede the growth of the market.
Netherlands Pharmaceutical Industry Segmentation
Pharmaceuticals are referred to as prescribed and non-prescribed drugs. These medicines can be bought by an individual with or without the doctor's prescription and are safe for consumption for various illnesses with or without the doctor's consent. The report also covers an in-depth analysis of qualitative and quantitative data. The Dutch pharmaceutical market is segmented by ATC/therapeutic class (alimentary tract and metabolism, blood and blood-forming organs, cardiovascular system, dermatological drugs, genitourinary system and reproductive hormones, systemic hormonal preparations, excluding reproductive hormones and Insulins, antiinfectives for systemic use, antineoplastic and immunomodulating agents, musculoskeletal system, nervous system, antiparasitic products, insecticides and repellents, respiratory system, sensory organs, and various ATC structure), and mode of dispensing (Prescription and OTC). The report offers values in USD million for all the above-mentioned segments.
By ATC/Therapeutic Class | |
Alimentary Tract and Metabolisma | |
Blood and Blood-forming Organs | |
Cardiovascular System | |
Dermatological Drugs | |
Genitourinary System and Reproductive Hormones | |
Systemic Hormonal Preparations, Excluding Reproductive Hormones and Insulins | |
Antiinfectives for Systemic Use | |
Antineoplastic and Immunomodulating Agents | |
Musculoskeletal System | |
Nervous System | |
Antiparasitic Products, Insecticides, and Repellents | |
Respiratory System | |
Sensory Organs | |
Various ATC Structures |
By Mode of Dispensing | |
Prescription | |
OTC |
Netherlands Pharmaceutical Market Size Summary
The Netherlands pharmaceutical market is poised for significant growth over the forecast period, driven by a combination of factors including a robust healthcare system, a highly educated workforce, and a government that fosters innovation. The country's strategic location and the presence of world-class research institutes make it an attractive hub for biopharmaceutical operations. Despite the initial setbacks caused by the COVID-19 pandemic, which impacted pharmaceutical sales due to lockdowns, the market is expected to recover and expand steadily. The increasing burden of chronic diseases such as cancer and cardiovascular conditions, along with rising healthcare expenditures, underscores the demand for new medicine development and infrastructure enhancements. However, government initiatives aimed at reducing drug prices may pose challenges to the profitability of pharmaceutical companies operating in the region.
The market landscape is characterized by moderate fragmentation, with several major players holding significant market shares. Companies like Abbott Laboratories, AbbVie Inc., and AstraZeneca PLC are actively engaging in acquisitions and joint ventures to strengthen their positions. The market is also witnessing a surge in product approvals and new drug launches, particularly in the prescription segment, which is driven by the rising prevalence of infectious diseases and chronic conditions. The introduction of new prescription-based drugs, such as Sanofi's Enjaymo and Tezspire, highlights the dynamic nature of the market. Despite challenges such as high product development costs and regulatory scrutiny, the Netherlands pharmaceutical market is expected to continue its growth trajectory, supported by ongoing research and development activities and increasing awareness of health issues among the population.
Netherlands Pharmaceutical Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Presence of Better Research Institutes, Excellent Healthcare System, and an Innovation-friendly Government
-
1.2.2 Rising Cases of Chronic Diseases
-
-
1.3 Market Restraints
-
1.3.1 High Failure Rate and Developing Cost of New Products
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By ATC/Therapeutic Class
-
2.1.1 Alimentary Tract and Metabolisma
-
2.1.2 Blood and Blood-forming Organs
-
2.1.3 Cardiovascular System
-
2.1.4 Dermatological Drugs
-
2.1.5 Genitourinary System and Reproductive Hormones
-
2.1.6 Systemic Hormonal Preparations, Excluding Reproductive Hormones and Insulins
-
2.1.7 Antiinfectives for Systemic Use
-
2.1.8 Antineoplastic and Immunomodulating Agents
-
2.1.9 Musculoskeletal System
-
2.1.10 Nervous System
-
2.1.11 Antiparasitic Products, Insecticides, and Repellents
-
2.1.12 Respiratory System
-
2.1.13 Sensory Organs
-
2.1.14 Various ATC Structures
-
-
2.2 By Mode of Dispensing
-
2.2.1 Prescription
-
2.2.2 OTC
-
-
Netherlands Pharmaceutical Market Size FAQs
How big is the Netherlands Pharmaceutical Market?
The Netherlands Pharmaceutical Market size is expected to reach USD 9.92 billion in 2024 and grow at a CAGR of 7.5% to reach USD 14.24 billion by 2029.
What is the current Netherlands Pharmaceutical Market size?
In 2024, the Netherlands Pharmaceutical Market size is expected to reach USD 9.92 billion.